Abstract Diabetic nephropathy (DN) is the most common cause of end-stage kidney disease in the USA and accounts for a significant increase in morbidity and mortality in patients with diabetes. Early detection is critical in improving clinical management. Although microalbuminuria is regarded as the gold standard for diagnosing the onset of DN, its predictive powers are limited. Consequently, great efforts have been made in recent years to identify better strategies for the detection of early stages of DN and progressive kidney function decline in diabetic patients. Here, we review the various urinary biomarkers that have emerged from these studies which hold promise as more sensitive diagnostic tools for the earlier detection of diabetic kidney disease and the prediction of progression to end-stage kidney disease. A number of key biomarkers present in the urine have been identified that reflect kidney injury at specific sites along the nephron, including glomerular/podocyte damage and tubular damage, oxidative stress, inflammation and activation of the intrarenal renin-angiotensin system. We also describe newer approaches, including urinary microRNAs, which are short noncoding mRNAs that regulate gene expression, and urine proteomics, that can be used to identify potential novel biomarkers in the development and progression of diabetic kidney disease.
Introduction
Diabetes mellitus is one of the most common chronic diseases, and its incidence continues to increase not just in adults but also in the pediatric population. A recent study based on Markov modeling projected that by year 2050 the U.S. population below the age of 20 years with type 1 or type 2 diabetes would increase by 1.2-3 fold and 1.5-4 fold, respectively [1] . The rising burden of diabetes has a significant impact on public health. Diabetic nephropathy (DN) is considered one of the major microvascular complications of diabetes and arguably the most devastating, given that those with kidney disease predominantly account for the increased morbidity and mortality among diabetic patients [2] . DN is the largest single cause of end-stage kidney disease (ESKD), underscoring the importance of early identification, treatment and prevention. There is a particular need to identify those at risk of DN in the pediatric population given the increasing prevalence of diabetes observed in youths and the ensuing diabetic kidney disease.
Microalbuminuria is the most widely used early clinical indicator of DN and has been recognized as a predictor of progression to ESKD in both type 1 [3] and type 2 diabetes [4] . However, there are attendant shortcomings of microalbuminuria as a diagnostic tool for the onset of diabetic kidney disease, and its predictive powers are limited. Some patients without microalbuminuria display advanced renal pathological changes, indicating that microalbuminuria may not be an optimal marker for the early detection of diabetic kidney disease [5, 6] . In some instances, patients with diabetes develop progressive loss of kidney function before the development of microalbuminuria [7, 8] . In other cases, patients with microalbuminuria at one point in time no longer have it when measured at a later time, and it is a poor predictor of the development of macroalbuminuria [9] . Microalbuminuria is not specific for the presence of diabetic kidney disease because it can occur in patients with diabetes without concurrent or future DN, as well as in nondiabetic patients with progressive chronic kidney disease (CKD) [10] . Therefore, there is an urgent need to identify more sensitive and specific biomarkers than microalbuminura for the early detection of diabetic kidney disease and prediction of progression to ESKD. To this end, there have been intensive investigations in recent years, and here we review the key urinary biomarkers that have emerged. A number of new and important biomarkers present in the urine have been identified, including biomarkers that reflect kidney injury due to glomerular/podocyte damage and tubular damage, oxidative stress, inflammation and activation of the intrarenal renin-angiotensin system (Fig. 1) . We also describe newer approaches, including urinary microRNAs and urine proteomics, used to identify potential novel biomarkers in the development and progression of diabetic kidney disease.
Biomarkers of glomerular damage
A key feature of glomerular damage in DN is characterized by changes in glomerular permeability and structure that can occur as a result of injury to any of the major components of the glomerular filtration barrier apparatus, including the glomerular basement membrane, podocytes and glomerular capillary endothelium. Glomerular damage results in the appearance in urine of an excess of serum proteins that are not normally freely filtered through the glomerulus, including macromolecules, such as albumin and transferrin, and extracellular matrix proteins [11] .
In normal individuals, only a small amount of albumin is filtered in the glomerulus, and it is subsequently reabsorbed by the tubules. The onset of microalbuminuria is currently used in clinical practice for diagnosing DN, but certain limitations, as discussed above, should be taken into consideration.
Transferrin
Transferrin is a serum protein that is very similar in molecular weight to albumin (76.5 vs. 65 kDa, respectively), but it is less anionic than albumin and presumably filtered more readily in the glomerulus [12] . Thus, urinary transferrin may be a more sensitive marker of glomerular damage in patients with diabetes. Indeed, elevated urinary transferrin excretion, or transferrinuria, has been reported in diabetic patients, even in those without albuminuria [13] . Cheung et al. found an abnormal urinary transferrin/creatinine ratio in up to 61 % of normoalbuminuric patients [14] , and Kanumi et al. reported that among patients with type 2 diabetes, 31 % of patients who exhibited transferrinuria at baseline subsequently developed microalbuminuria, compared with 7 % of patients without transferrinuria [15] . Based on such findings, various authors have proposed that increased transferrinuria can be considered a predictor of the development of microalbuminuria in normoalbuminuric type 2 diabetic patients [15, 16] . Increased urinary transferrin excretion has also been reported in children with type 1 diabetes and correlated significantly with urinary albumin excretion [17] . In patients who already exhibit albuminuria, urinary transferrin excretion has a linear relationship with urinary albumin excretion, and in the study of Cheung et al., increased transferrinuria was found in 95 % of microalbuminuric patients and 100 % of macroalbuminuric Fig. 1 Urinary biomarkers of diabetic nephropathy that reflect kidney injury due to glomerular/ podocyte damage and tubular damage, growth factors, oxidative stress, inflammation and activation of the intrarenal reninangiotensin system patients [14] . Transferrinuria may be a more sensitive indicator for earlier detection of DN than microalbuminuria, as well as a predictor of the development of microalbuminuria. However, urinary transferrin excretion, like albumin, is also elevated in other diseases that affect the glomerulus, such as primary glomerulonephritis, and is not specific to DN [18] .
Podocyte injury
Podocyte injury has been reported as an early feature of DN [19] . A reduction in podocyte number and density per glomerulus has been linked to the development of proteinuria and the progression of diabetic kidney disease in patients with diabetes [20] . Studies in which podocytopenia was reported in normoalbuminuric patients suggest that podocyte lesions exist before the development of proteinuria [20, 21] . A number of podocyte-specific proteins have been examined for their potential roles as biomarkers of early DN and progression of diabetic kidney disease.
Nephrin
Nephrin is a transmembrane protein of the immunoglobulin superfamily and is a key molecular component of the glomerular filtration slit diaphragm between adjacent podocytes. Its expression is known to be altered in experimental models of diabetes and also in various human proteinuric diseases, including diabetes [22] . A recent investigation by Jim et al revealed that nephrinuria was present in 100 % of type 2 diabetic patients with microalbuminuria and macroalbuminuria [23] . Interestingly, nephrinuria has also been found to be present in 54 % of the type 2 diabetic patients with normoalbuminuria [24] . Similarly, in another study, nephrinuria was observed in 30 % of normoalbuminuric type 1 diabetic patients, as well as 28 % of patients previously normoalbuminuric but subsequently testing positive for microalbuminuria, whereas none of the nondiabetic control subjects had nephrinuria [20] . While further research is needed to confirm the above findings, urine nephrin levels could be a good biomarker of early diabetic kidney disease, as it appears to precede the development of microalbuminuria.
Podocalyxin
Podocalyxin, a sialoglycoprotein, is the major constituent of the glycocalyx of podocytes and is responsible for the highly negative surface charge of podocytes. In addition to other podocytopathies in glomerular disease, microvillous transformations containing podocalyxin appear on the apical surface of injured podocytes, and these are shed into urine. Hara et al. quantified such shedding of vesicles using a highly sensitive enzyme-linked immunosorbent assay (ELISA) to detect urinary podocalyxin in patients with type 2 diabetes [24] . Interestingly, elevated levels of urinary podocalyxin were observed in 53.8 % of normoalbuminuric patients, indicating that urinary podocalyxin might be a useful biomarker for detecting early podocyte injury in diabetic patients [24] . Moreover, urinary mRNA profile studies suggest that quantification of mRNA expression of podocalyxin, as well as of other podocyte-associated molecules, such as synaptopodin, α-actinin-4, and podocin, may be useful biomarkers for detecting early podocyte injury and the progression of diabetic kidney disease [25, 26] . However, the strategy of utilizing urinary mRNA is limited by the susceptibility for mRNA degradation by the presence of RNAses. There is also the issue of specificity, given that podocalyxin expression is not restricted to podocytes, but is also expressed in endothelial cells, parietal epithelial cells and a variety of nonrenal cells, such as platelets and hematopoietic stem cells [27] .
Wilms Tumor-1 Wilms Tumor-1 (WT1) is a zinc-finger transcription factor that plays an important role in podocyte maturation [19, 21] . In the mature glomerulus, the expression of WT1 is limited to podocytes. Kubo et al. were the first to report the detection of endogenous WT1 mRNA in the urine of patients with renal diseases, including DN [28] . More recently, WT1 protein in urinary exosomes has been isolated from spot urine samples of patients with type 1 diabetes, and higher levels were associated with significant increases in the urine protein-to-creatinine ratio, albumin-to-creatinine ratio and serum creatinine levels, as well as a decline in estimated glomerular filtration rate (eGFR) [21] . Interestingly, 50 % of diabetic patients without proteinuria were also positive for urinary WT1 protein, while nondiabetic control subjects showed an almost absent level of WT1 [21] . These findings suggest that urinary WT1 protein levels could serve as a podocyte-specific biomarker for the early diagnosis of diabetic kidney disease and prediction of renal outcome.
Vascular endothelial growth factor A Vascular endothelial growth factor A (VEGF-A) represents another potential podocyte-derived biomarker that has been implicated in DN. It is constitutively expressed in the podocytes, and autocrine/paracrine VEGF-A signaling occurs between podocytes and the adjacent glomerular endothelial cells, which express the VEGF receptors VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1). In diabetes, particularly in the early stages of development of diabetic kidney disease, an upregulation of VEGF-A expression has been demonstrated; this was paralleled by an increase in urinary protein levels of VEGF and the soluble form of VEGFR-1 (sFlt-1) in type 2 diabetic patients with microalbuminuria [29] . The authors of this study also reported that the urinary excretion of VEGF was significantly higher in the diabetic groups, even at the normoalbuminuric stage, than in the nondiabetic healthy control group and that urinary VEGF levels increased as DN advanced [29] . These results suggest that urinary VEGF might be useful as a sensitive marker of DN, particularly during the earlier stage, and for predicting disease progression.
Glomerular endothelial injury
Endothelial dysfunction has long been implicated as a major mechanism for diabetic kidney disease and other microvascular complications in diabetes [30] . Recent investigations have demonstrated that glomerular endothelial cells have a gel-like layer of glycocalyx on their luminal surface that covers the fenestrae. The endothelial glycocalyx, comprising proteoglycans, glycosaminoglycan (GAG) chains and sialoglycoproteins, has an important barrier function with an albumin-restricting ability [31] . Heparan sulfate and chondroitin sulfate represent the majority of the sulfated GAG chains in the endothelial glycocalyx. Hyperglycemia has been shown to result in endothelial glycocalyx damage through a reduced synthesis of GAGs by the glomerular endothelial cells. Damage to the endothelial glycocalyx disrupts normal microvascular permeability and is associated with the onset of microalbuminuria in diabetic patients [31, 32] . Studies show that diabetic patients excrete significantly more GAGs than control patients [32] . Moreover, increased levels of urinary GAGs have been detected in patients with microalbuminuria or macroalbuminuria, with the increases positively correlated with the duration of DN [33] .
The assessment of urinary GAG levels could potentially be a good marker for diabetic kidney disease. In particular, it may be useful for determining endothelial dysfunction in the early stages of DN and the progression of the disease. However, there are a number of points that need to be considered. While some studies reported increased urinary GAGs in diabetics, including normoalbuminuric patients, others have reported either no significant differences between normoalbuminuric diabetics and healthy nondiabetic control subjects, or a decrease in GAG excretion with an increase in urinary albumin excretion [34] . It should be noted that GAGs are also major components of basement membranes, including the tubular basement membrane. Studies show a correlation between urinary GAG excretion and urinary markers of tubular damage, such as Tamm-Horsfall protein [34] . These findings suggest that the excretion of GAG may actually reflect tubular dysfunction in diabetic patients.
Glomerular/tubular basement membrane and extracellular matrix proteins
Type IV collagen is a high-molecular-weight protein (approximately 540 kDa) that forms a major component of the glomerular and tubular basement membranes and the mesangial matrix, and it is not normally filtered through the glomerulus [35] . Urinary type IV collagen has been shown to be significantly elevated in type 2 diabetic patients, compared with healthy nondiabetic individuals, with the increase positively correlated with the degree of albuminuria. In normoalbuminuric diabetic patients, there is experimental evidence indicating that increases in urinary type IV collagen levels may precede the appearance of microalbuminuria [35] [36] [37] . Moreover, recent studies report a correlation between high urinary type IV collagen excretion and the annual decline in eGFR in patients with type 1 or type 2 diabetes without overt proteinuria [38, 39] . Hence, in patients with DN, the urinary excretion of type IV collagen may be more useful as an earlier biomarker than albuminuria. However, it remains unclear whether it will prove to be a reliable predictor of the progression of kidney function decline in diabetic patients, rather than a mere association.
It is well established that the hallmark of DN is the excessive production and accumulation of extracellular matrix proteins in the mesangium and basement membrane of the glomerulus. Besides type IV collagen, studies suggest that urinary mRNA levels of fibronectin, α-smooth muscle actin, and matrix metalloproteinase (MMP)-9 might be novel biomarkers of diabetic kidney disease [40] . Urinary MMP activities were noted to be increased in adolescents aged 12-19 years with early stages of type 1 diabetes [41] . Fibronectin is an intrinsic component of the glomerular extracellular matrix. Its expression is increased in DN, and urinary fibronectin has been shown to be increased in type 1 diabetic patients with macroalbuminuria, and in type 2 diabetic patients with microalbuminuria and macroalbuminuria [42, 43] . However, it remains uncertain whether urinary fibronectin might be a clinically useful biomarker of early DN, and further studies are necessary to determine its potential superiority compared to microalbuminuria.
Growth factors
Transforming growth factor-beta Transforming growth factor-beta (TGF-β) is a potent inducer of extracellular matrix proteins and is generally regarded as a central mediator in the pathogenesis of DN. TGF-β-induced protein h3 (βig-h3) is an extracellular matrix protein that has been used to assess the biological activity of TGF-β in the kidney [44] . In one study, the ratio of βig-h3 to creatinine in urine was noted to be elevated in type 2 diabetic patients with normoalbuminuria (101.6±9.27), microalbuminuria (120.2± 14.48) and overt proteinuria (146.3±16.34), compared with healthy control subjects (64.8±7.14) [45] . In another study, urinary excretion of βig-h3 was significantly higher in the diabetic patients than in the controls, even in the normoalbuminuric stage, and urinary βig-h3 levels increased significantly with advancing diabetic nephropathy [46] . Together, these studies suggest that the longitudinal monitoring of urinary βig-h3 may detect DN at an earlier stage and that βig-h3 could be a sensitive marker of diabetic kidney disease progression. Urinary levels of TGF-β have been found to increase in type 2 diabetic patients compared with nondiabetic controls [47] , as well as in young type 1 diabetic patients [48] , and patients with DN had higher urinary TGF-β1 levels than normoalbuminuric patients with diabetes and healthy controls [49] . Sato et al. reported that patients with type 2 diabetes had increased urinary TGF-β1 excretion that correlated with albuminuria and mesangial expansion [50] , suggesting that urinary TGF-β concentration might be a useful marker of renal TGF-β expression and diabetic kidney disease. However, the results of prospective studies aimed at assessing the prognostic value of urinary TGF-β1 have been mixed. One report concluded that urinary TGF-β1 predicted the rate of renal function decline and progression of diabetic nephropathy after a mean follow-up of 2 years [51] , whereas another did not [52] .
Connective tissue growth factor
Connective tissue growth factor (CTGF) has emerged as an important modulator of pro-fibrotic TGF-β activities and promotes renal fibrosis. A large cross-sectional study of 318 type 1 diabetic patients found that urinary CTGF levels correlated with urinary albumin excretion and increased in those with DN [53] . A subsequent prospective study of type 1 and type 2 diabetics followed-up for 6 years demonstrated that urinary CTGF levels correlated with the progression of microalbuminuria, demonstrating the potential usefulness of urinary CTGF levels as a prognostic biomarker for early progression of diabetic nephropathy [54] .
Cystatin C
Cystatin C, a cysteine protease inhibitor, is a 13-kDa protein that is freely filtered by the glomerulus and has been identified as a promising marker to estimate GFR. Serum cystatin C has been shown to be more accurate than serum creatinine in the overall estimation of GFR in type 2 diabetic patients [55] , and urinary cystatin C has been associated with the decline of eGFR [56] . A recent prospective study in type 2 diabetics demonstrated that there was a significant association between increases in urinary cystatin C and a decline in GFR, particularly at the early stages of nephropathy in patients with an eGFR of ≥60 mL/min/1.73 m 2 , and that this was correlated with progression to CKD stage 3 or greater [56] . These findings suggest that urinary cystatin C may be a sensitive biomarker for early detection and prediction of kidney impairment in type 2 diabetic patients. Further studies are needed in larger cohorts and with longer follow-up periods to confirm these findings. It should also be noted that the filtered cystatin C is almost entirely reabsorbed in the proximal tubule, as with other low-molecular-weight proteins, with virtually no tubular secretion of cystatin C; as such, increases in urinary cystatin C, independent of serum cystatin C, suggest renal tubular damage rather than solely glomerular damage [57] . Other biomarkers of tubular damage will be discussed below.
Biomarkers of tubular damage
Although the importance of the glomerular filtration barrier in the development of albuminuria and diabetic kidney disease is well known, it has been suggested that the rate of decline in kidney function correlates better with the degree of tubular injury and tubulointerstitial fibrosis [58] . Furthermore, the results of recent studies have renewed interest in the role of proximal tubule reabsorption of urinary albumin in the glomerular filtrate, suggesting that albumin filtration under physiologic conditions is greater than previously determined and that proximal tubule cell (PTC) damage alone can lead to the development of albuminuria [59] . The proximal tubule may play a greater role in the development of albuminuria than previously thought and, hence, some markers of tubular damage may be more sensitive than microalbuminuria during the very early stages of diabetic nephropathy, independent of defects in glomerular permeability [60] .
Megalin and cubilin
Receptor-mediated endocytosis via clathrin-coated vesicles is a central mechanism responsible for protein reabsorption in the proximal tubule [61] . This process involves two apical membrane receptors, namely, megalin and cubilin, that interact with high affinity. Megalin is an approximately 600-kDa transmembrane protein belonging to the low-density lipoprotein (LDL) receptor family, and cubilin is a slightly smaller peripheral membrane protein, approximately 460 kDa, also known as the intrinsic factor-cobalamin receptor [61, 62] . Most proteins that are filtrated through glomeruli have been identified as ligands of megalin, cubilin or both. Albumin binds both megalin and cubilin. Cubilin is required for the uptake of albumin by PTCs, and megalin drives endocytosis of the cubilin-albumin complex [62] . Studies by Thrailkill et al. demonstrated that urinary megalin and cubilin excretion was significantly elevated in microalbuminuric patients with type 1 diabetes as a result of proximal tubule shedding of these proteins, possibly by enhanced MMP activity in the diabetic kidney [63] . Ogasawara et al. subsequently demonstrated that the urinary full-length form of megalin increased in correlation with the severity of DN in patients with type 2 diabetes [64] . In this study, the urine levels of megalin in normoalbuminuric patients were significantly higher (39 % over the normal cut-off value) than those in normal control individuals, implying that the urinary megalin assay is sufficiently sensitive for the early diagnosis or prediction of the development of DN. Larger prospective cohort studies are needed to confirm the utility of megalinuria or cubilinuria as predictive markers for early diabetic kidney disease.
α1-microglobulin and retinol-binding protein
Low-molecular-weight plasma proteins whose excretion in the urine is increased due to deficient tubular reabsorption have also been described as biomarkers of tubular damage. Increased urinary excretion of α1-microglobulin [65] and retinol-binding protein [66] has been reported in patients with type 2 diabetes compared with healthy control subjects. Both α1-microglobulin and retinol-binding protein are lowmolecular-weight proteins, and their unbound forms are freely filtered and then reabsorbed by the PTCs. Reduction in proximal tubule function results in increased excretion of these proteins in the urine. Moreover, urinary levels of both α1-microglobulin and retinol-binding protein were elevated in some normoalbuminuric patients with diabetes [65] [66] [67] . However, serum levels can affect urinary levels of α1-microglobulin and retinol-binding protein, and their predictive value to detect early DN is not enough to replace microalbuminuria.
NGAL and KIM-1
Neutrophil gelatinase-associated lipocalin (NGAL), a member of the lipocalin family, was originally identified as a 25-kDa protein that is covalently associated with gelatinase from human neutrophils. NGAL is produced in the distal nephron and upregulated in response to kidney injury [68] . Kidney injury molecule 1 (KIM-1), a type 1 transmembrane protein present on the apical membrane of PTCs, is also upregulated in acute kidney injury. Both urine NGAL and urine KIM-1 were found to be elevated in patients with type 1 diabetes, with or without albuminuria, indicating tubular damage at an early stage [69] , and higher urine NGAL and urine KIM-1 levels were found to be predictive of a faster decline in eGFR in patients with type 2 diabetes [70] . A recent cross-sectional study aimed at investigating the prevalence of tubular damage in the early stage (<5 years) of type 2 diabetes demonstrated that urine NGAL and urine KIM-1 levels were significantly increased in the diabetic group compared with the control group [71] . Moreover, urine NGAL showed a stronger positive correlation with the urine albumin/creatinine ratio and a negative correlation with eGFR, whereas urine KIM-1 was not significantly different among the three diabetic groups (normoalbuminuria, microalbuminuria and macroalbuminuria) and did not correlate with either the urine albumin/creatinine ratio or eGFR [71] . These findings indicate that tubular damage is relatively common at the early stage of type 2 diabetes and that urine NGAL may be a promising biomarker for the early detection and monitoring of kidney impairment in type 2 diabetes.
Biomarkers of oxidative stress
Oxidative stress is well recognized as an important causative factor in the development of DN. Hyperglycemia and the diabetic milieu induce cellular superoxide overproduction and the activation of pathways associated with the pathogenesis of diabetes complications, such as polyol pathway activation, advanced glycation end-product overproduction and the activation of protein kinase C isoforms [72] . 8-Hydroxy-2′-deoxyguanosine (8-OHdG) and 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG) are products of oxidative DNA damage that are freely filtered, and thus their urinary levels serve as an index of systemic oxidative stress [73] . Urinary excretion of 8-OHdG is markedly increased in patients with type 2 diabetes compared to healthy control subjects, and a high level of urinary 8-OHdG has been found to be associated with high glycosylated hemoglobin [73] as well as the severity of the tubulointerstitial lesion [72] . Moreover, a prospective longitudinal study demonstrated that elevated urinary 8-oxodG excretion at baseline was associated with the development of nephropathy 5 years later, and urinary 8-oxodG was identified as the strongest predictor for development of this complication among several risk factors examined [74] . A significant correlation between a higher excretion of 8-oxodG in urine and progression of DN has been seen [74, 75] . Taken together, the results of these studies indicate that urinary 8-OHdG and 8-oxodG may be useful biomarkers to predict the development of DN. However, conflicting results were obtained by Serdar et al. in a more recent study [76] . In this study, even though urine 8-OHdG levels increased in diabetic patients, these authors found that urine 8-OHdG level was not as useful a clinical marker as the urine albumin/creatinine ratio in predicting the patients at risk of developing DN [76] .
Biomarkers of inflammation
Growing evidence indicates that immunologic and inflammatory mechanisms play a significant role in disease development and progression in DN. Some studies suggest that individuals who develop diabetic kidney disease have low-grade inflammation years before the onset of the disease and that elevated excretion of inflammatory markers in urine is associated with early progressive renal function decline in type 1 diabetic patients [77] . Tumor necrosis factor-alpha (TNF-α) is a key mediator of inflammation and a major participant in the pathogenesis of kidney injury by promoting inflammation, apoptosis and the accumulation of extracellular matrix, thereby reducing GFR and increasing albumin permeability. Although activated macrophages are the major source of TNF-α, intrinsic renal cells are also able to express TNF-α and contribute to renal injury [78] . A recent investigation by Navarro et al. revealed that urinary TNF-α excretion increased in patients with type 2 diabetes compared to control subjects and that this increase was associated with urinary albumin excretion and correlated with the severity of DN [79] . Together, these results indicate that TNF-α may have potential as a useful urinary biomarker for DN.
Biomarkers of the intrarenal renin-angiotensin system
An activated intrarenal renin-angiotensin system (RAS) has been implicated as a crucial player in the pathogenesis of DN. It is widely thought that blockade of components of the RAS through the use of drugs, such as an angiotensin-converting enzyme (ACE) inhibitor, which inhibit the local production and/or local effects of angiotensin II exerts renoprotective effects [80] . Angiotensinogen (AGT) is constitutively secreted in the proximal straight tubule and because AGT is the only known substrate for renin, increased intrarenal AGT levels contribute to angiotensin II generation [81] . Studies have shown that urinary AGT is highly correlated to renal tissue expression of angiotensin II and, therefore, a potentially suitable marker of intrarenal RAS activity [82, 83] . Moreover, urinary AGT is associated with an increased risk for the deterioration of renal function in patients with CKD and, consequently, predictive of GFR loss in longitudinal studies [83] .
In a recent study, van den Heuvel and colleagues demonstrated that urine renin levels were increased in diabetic patients and that treatment with an ACE inhibitor and/or angiotensin receptor blocker (ARB) reduced urinary renin, but not AGT, despite elevated plasma renin levels [84] . These results indicate that urinary renin reflects renal RAS activity and the efficacy of RAS blockade in the kidney. Further studies show that the urine/plasma ratio of renin was more than 100-fold higher than that of AGT and albumin and that it was reduced by fourfold by a single RAS blockade and by more than tenfold by dual RAS blockade [85] . In contrast, reductions in urinary AGT paralleled changes in albuminuria, and the urine/ plasma ratio of AGT was identical to that of albumin under all conditions, suggesting that urinary AGT is a marker of filtration barrier damage rather than of intrarenal RAS activity [85] . These findings suggest that the urine/plasma renin ratio, and not urine renin alone, may reflect the renal efficacy of RAS blockade and that this ratio can serve as a very sensitive early marker of intrarenal RAS activation and DN.
Urinary microRNA (miRNA)
In recent years, a novel class of naturally occurring short noncoding RNA called microRNA (miRNA) has emerged as important post-transcriptional regulators of gene expression, capable of regulating numerous biological functions. Considerable attention has recently focused on the role of miRNAs as mediators or biomarkers of diseases, including DN. It is also noteworthy that most miRNAs which have been implicated in nephropathy are regulated by the profibrotic cytokine TGF-β [86] . The use of urinary miRNA as biomarkers of kidney disease is currently being actively investigated. A recent study by Szeto et al. examined the urinary miRNA expression profiles in patients with CKD from various etiologies, including immunoglobulin A (IgA) nephropathy, diabetes and hypertension, and found that these differed between the groups [87] . Patients with diabetic glomerulosclerosis had lower urinary miR-15 expression than the other groups. In addition, urinary miR-21 and miR-216a expression correlated with the rate of kidney function decline and risk of progression to dialysisdependent kidney failure regardless of the type of CKD [87] . Argyropoulos et al. identified a set of 27 differentially expressed miRNAs in urine samples from patients with type 1 diabetes in different stages of DN whose renal outcomes had been ascertained after >20 years of follow-up [88] . Although these studies bear limitations, including the relatively low number of patients studied and differences in therapies among the patients, such as receiving or not receiving ACE inhibitors and/ or ARBs, the results underscore the potential value of urinary miRNAs as molecular signatures associated with distinct clinical stages of diabetic kidney disease and suggest the possibility that changes in miRNA expression may be early indications of kidney injury in diabetes. Further investigations that include larger cohorts are still necessary to determine whether urinary miRNA expression profiles would prove to be ideal biomarkers for early diagnosis and risk stratification of DN.
Urine proteomics
Proteomics is a method aimed at large-scale study of proteins that allows a simultaneous examination of the patterns of multiple urinary and plasma proteins. Urine proteome analysis is rapidly emerging as a tool for facilitating the diagnosis and prognosis of disease states, and the technology of highresolution protein separation by capillary electrophoresis together with mass spectrometry allows enables an unbiased search for potential new biomarkers. Recent studies using this approach identified a set of biomarkers for DN with a sensitivity and specificity of 97 % in type 1 diabetic patients [89] , and 93.8 % sensitivity and 91.4 % specificity in type 2 diabetics [90] . These studies identified urinary proteomic biomarkers that are distinct for patients who had Podocin α-Actinin-4 Synaptopodin
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Cross-sectional -Correlated with albuminuria, duration, severity, control of diabetes [65] microalbuminuria and diabetes and who subsequently progressed toward overt DN, and allow the early detection of DN, or its discrimination from other nondiabetic CKD or the prediction of normoalbuminuric diabetic patients prone to develop DN [89, 90] . However, these studies defined DN exclusively on the clinical basis of presence of macroalbuminuria with or without a decline of eGFR, but without histological verification. Studies by Papale et al. used the technique of surface-enhanced laser desorption/ionizationtime of flight/mass spectrometry (SELDI-TOF/MS) to determine a urine proteomic fingerprint defining a set of biomarkers able to reliably identify biopsy-proven DN in type 2 diabetic patients and differentiate DN from nondiabetic CKD in both patients with and without diabetes [91] .
To evaluate urinary proteome analysis as a tool for predicting DN, Zürbig et al. examined urine samples from a longitudinal cohort of patients with type 1 and 2 diabetes using a previously generated CKD biomarker classifier and capillary-electrophoresis/MS to assess the low-molecular weight proteome, referred to as the "peptidome" [92] . The application of the classifier system was able to identify normoalbuminuric subjects who 5 years later developed macroalbuminuria and was superior in this regard to microalbuminuria as a predictor as it enabled the early detection of subsequent progression to macroalbuminuria [92] . Interestingly, many of the biomarkers were fragments of collagen type I, and quantities were reduced in patients with diabetes or DN. The decrease in collagen fragments preceded the increase in albumin excretion 3-5 years before the onset of macroalbuminuria, suggesting that extracellular matrix changes and collagen turnover may be highly indicative of the molecular pathophysiology of diabetes [92] . A recent prospective case-control study examined the value of a urinary proteomic-based risk score, or classifier, in predicting the development and progression of microalbuminuria in patients with type 2 diabetes based on 273 urinary peptides [93] . The study found that the proteomic classifier was independently associated with the transition to microalbuminuria or macroalbuminuria and that it predicted the progression of albuminuria. Altogether, urinary proteomic-based biomarker discovery represents a novel strategy to identify earlier and more specific biomarkers than urinary albumin and enables early renal risk assessment in patients with diabetes.
Conclusion
Over the last few decades, there has been tremendous interest in the discovery of biomarkers of DN that allow for the detection of early stages of DN and progressive kidney function decline in diabetic patients. Recent studies have highlighted a number of promising new biomarkers, including plasma concentrations of the TGF-β to bone morphogenetic protein-7 Neutrophil gelatinase-associated lipocalin (NGAL) Kidney injury molecule 1 (KIM-1)
T1DM
Cross-sectional -Both are elevated in diabetic patients with and without albuminuria [69] T2DM Longitudinal -Higher levels were predictive of a faster decline in eGFR [70] T2DM
Cross-sectional -Both are elevated in early stage (<5 years) of diabetes -Urine NGAL with stronger positive correlation with urine albumin/creatinine ratio [71] 8-Hydroxy-2′-deoxyguanosine (8-OHdG) 8-Oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG)
T2DM
Longitudinal -High urinary excretion at baseline was associated with the development of nephropathy 5 years later [74] Tumor-necrosis factor-alpha (TNF-α)
Cross-sectional -Correlated with urinary albumin excretion, and the severity of DN [79] Renin T1/T2DM
Cross-sectional -Increased in diabetic patients, treatment with ACE inhibitor and/or ARB reduced urinary renin, despite elevated plasma renin levels [84] miRNAs
T1DM
Historical cohort -Urinary microRNA profiles differ across the different stages of DN whose renal outcomes were ascertained after >20 year follow-up [88] T1/T2DM, Type 1/type 2 diabetes mellitus; CKD, chronic kidney disease; DN, diabetic nephropathy; GFR, glomerular filtration rate, ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker ratio [94] and TNF receptors 1 and 2 [95, 96] . A number of new and important biomarkers present in the urine have also emerged. However, in clinical practice, they have yet to replace the use of microalbuminuria, which remains the gold standard for detecting diabetic kidney disease. Some of the clinical studies exploring the urinary biomarkers associated with diabetic kidney disease are discussed in this review and are summarized in Table 1 . Limitations of the majority of these studies include their small sample size, or their cross-sectional or short-term prospective nature. Various biomarker detection methods were employed. The majority of the biomarkers were assayed by immunoassays, primarily ELISA. The strategies to determine urinary mRNA profiles, such as in the studies of podocyte-associated molecules (podocalyxin, synaptopodin, α-actinin-4, podocin) [25, 28] and of expression levels, such as TNF-α [79] , by reverse transcription-PCR may be limited by the susceptibility for mRNA degradation due to the presence of RNAses The analysis of biomarkers of renal injury in urinary exosomes represents an alternative approach. Exosomes can be recovered from the urine by differential centrifugation as a lowdensity membrane fraction. The use of exosome isolation provides an advantage for the detection of low-abundance urinary proteins by allowing marked (>30-fold) enrichment of constituent proteins, including intracellular proteins and transcription factors, such as WT1 [21] . The newer molecular technologies, such as quantitative PCR to detect urine miRNAs [88] and urine proteomics are associated with increased costs. Nevertheless, the utilization of urinary biomarkers might be a sensitive, noninvasive and clinically useful method that is particularly attractive given that urine is an easily available source. Future efforts should be directed at both discovering and validating new urinary biomarkers and conducting larger longitudinal prospective studies to confirm the utility of these biomarkers as more reliable, more predictive and prognostic markers of diabetic kidney disease and progression .
